Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs ImmunityBio, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry giants is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and ImmunityBio, Inc. over the past decade.

Teva's Consistent Leadership

Teva has consistently maintained a robust SG&A expenditure, peaking in 2016 with approximately $5.1 billion. Despite a gradual decline, Teva's expenses remained significantly higher than ImmunityBio's, underscoring its expansive operational scale.

ImmunityBio's Growth Trajectory

Conversely, ImmunityBio's SG&A expenses have shown a remarkable upward trend, increasing by nearly 3000% from 2014 to 2023. This surge reflects the company's aggressive growth strategy and expanding market presence.

Insights and Implications

While Teva's expenses highlight its established market position, ImmunityBio's rising costs suggest a dynamic shift towards innovation and expansion. Investors and stakeholders should consider these trends when evaluating future prospects.